Diabetes, Vol 44, Issue 1 67-74, Copyright © 1995 by American Diabetes Association

ARTICLES

A novel insulin secretagogue is a phosphodiesterase inhibitor

MD Leibowitz, C Biswas, EJ Brady, M Conti, CA Cullinan, NS Hayes, VC Manganiello, R Saperstein, LH Wang, PT Zafian and al. et
Department of Molecular Endocrinology, Merck Research Laboratories, Rahway, New Jersey 07065-0900.

The arylpiperazine L-686,398 was described as an oral hypoglycemic agent and is shown to be an insulin secretagogue in vitro. The characteristics of its activity were similar to those of the incretin glucagon-like peptide I (GLP-I). We demonstrate that both the peptide and L-686,398 increase the accumulation of cAMP in isolated ob/ob mouse pancreatic islet cells, but by different mechanisms. Although GLP-I activates adenylate cyclase, the arylpiperazine has no effect on this enzyme or on the binding of 125I-labeled GLP-I to its receptor on RINm5F rat insulinoma cell membranes. However, L-686,398 inhibits the total cAMP phosphodiesterase (PDE) activity in homogenates of ob/ob mouse pancreatic islets with an EC50 of approximately 50 mumol/l. To determine the mechanism of PDE inhibition by the arylpiperazine and to examine its specificity, we studied the kinetics of arylpiperazine inhibition of two recombinant PDEs. The arylpiperazine is a competitive inhibitor of both a human heart type III PDE and a rat type IV-D PDE. Inhibition of the type III and IV isozymes are characterized by Ki values of 27 and 5 mumol/l, respectively. Although not extremely potent, the arylpiperazine does exhibit modest selectivity between these PDEs. The observation that L-686,398 acts as a PDE inhibitor suggests that exploration for beta-cell-specific PDE isoforms may reveal novel PDEs as targets for the development of therapeutically useful glucose-dependent insulin secretagogues.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				F. Vandeput, S. L. Wolda, J. Krall, R. Hambleton, L. Uher, K. N. McCaw, P. B. Radwanski, V. Florio, and M. A. Movsesian Cyclic Nucleotide Phosphodiesterase PDE1C1 in Human Cardiac Myocytes J. Biol. Chem., November 9, 2007; 282(45): 32749 - 32757. [Abstract] [Full Text] [PDF]

				R. R. Miller, G. A. Doss, and R. A. Stearns IDENTIFICATION OF A HYDROXYLAMINE GLUCURONIDE METABOLITE OF AN ORAL HYPOGLYCEMIC AGENT Drug Metab. Dispos., February 1, 2004; 32(2): 178 - 185. [Abstract] [Full Text] [PDF]

				M. Conti Phosphodiesterases and Cyclic Nucleotide Signaling in Endocrine Cells Mol. Endocrinol., September 1, 2000; 14(9): 1317 - 1327. [Full Text]

				A. M. Gray, Y. H. A. Abdel-Wahab, and P. R. Flatt The Traditional Plant Treatment, Sambucus nigra (elder), Exhibits Insulin-Like and Insulin-Releasing Actions In Vitro J. Nutr., January 1, 2000; 130(1): 15 - 20. [Abstract] [Full Text]